ClinicalTrials.gg
Active, not recruitingNCT04152499MK-2870-001Updated Oct 9, 2026

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

A Phase 1/2 interventional study of SKB264 in Epithelial Ovarian Cancer, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Klus Pharma Inc.. Active, not recruiting at 109 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Klus Pharma Inc. · Phase 1/2, Interventional, and Treatment

Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,410
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Carcinoma, Ovarian Epithelial with a site in China — 30 open to participants now, 37 under way, 11 of them phase 3. Carcinoma, Ovarian Epithelial · China.

Enrollment
Largest of 53
1,410 · median 94
Started
2020
with 8 others
Phase 1/2
5 of 71
4 open now
Primary completion
2025-11
later than 13 of 36 live
Registered
17th of 71
by date

Among the 71 studies in Carcinoma, Ovarian Epithelial with a site in China, this one has the largest enrollment of the 53 interventional ones that give a count, is one of 9 that started in 2020, is one of 5 in phase 1/2, reaches primary completion later than 13 of the 36 other live ones, and was the 17th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

30 of the 71 studies in Carcinoma, Ovarian Epithelial with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carcinoma, Ovarian Epithelial with a site in China, or all of them as a file.
02

Study summary

A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

  1. Triple negative breast cancer
  2. Epithelial ovarian cancer
  3. Non-small cell lung cancer
  4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma
  5. Small cell lung cancer
  6. HR+/ HER2-breast cancer
  7. Head and neck squamous cell carcinoma
  8. Endometrial carcinoma
  9. Urothelial carcinoma
  10. Cervical cancer
Read the detailed description

This is an open label, Phase I-II, first in human (FIH) study for SKB264 as monotherapy in patients who have locally advanced unresectable or metastatic solid tumor that is refractory to all standard therapies. TROP2 (trophoblast antigen 2) assessments will not be performed prior to enrollment but it will be assessed retrospectively. Confirmation of TROP2 (trophoblast antigen 2) expression by immunohistology or other means is not required, but the Sponsor will request fresh tumor biopsy or tissue specimens from archived materials for determination of TROP2 (trophoblast antigen 2) expression retrospectively. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy whose tumor is refractory to standard therapies. Patients will receive study drug as a single IV infusion at the prescribed dose level at each administration. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).

03

Conditions studied

  • Epithelial Ovarian Cancer
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Urothelial Carcinoma
  • Non-Small Cell Lung Cancer
  • Small-Cell Lung Cancer
  • Endometrial Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Breast Cancer
  • Cervical Cancer

Keywords

  • TROP2, ADC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Diagnosis and Main Criteria for Inclusion:

Inclusion criteria

Inclusion Criteria:

Patients must meet the following criteria for inclusion into the study:

Phase I:

  1. Patients must be able to provide documented voluntary .
  2. Male or female patient aged 18-75 years.
  3. documented, incurable, locally advanced or epithelial origin malignant cancer, priority to include but not limited to the following tumor types:

    Breast cancer Ovarian epithelial cancer Non-small cell lung cancer Gastric adenocarcinoma Small cell lung cancer Urothelial carcinoma Note: Confirmation of TROP2 expression by immunohistology or other means is not required, but the Sponsor will request tissue specimens from fresh or archived materials for determination of TROP2 expression.

  4. by CT/MRI during dose escalation.
  5. Patients should have an unresectable locally advanced or metastatic solid tumor that is to standard therapies, or have no standard therapies, or standard treatment is not applicable at this stage.
  6. Granulocyte count ≥ 1.5×109/L, count ≥ 100×109/L, and ≥ 9 g/dL.
  7. (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×.
  8. Serum ≤ 1.5 mg/dL (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ×ULN may be enrolled)., (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
  9. ≥ 50 mL/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration, or Modification of Diet in Renal Disease formulas. Note that 24 hour urine collection is not required but is allowed.
  10. (ECOG) Performance Status 0 or 1.
  11. For female patients of and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of during study treatment. Female and male patient treated with SKB264 should continue contraception use for 7 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.

    • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.
    • Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
  12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
  13. Expected survival ≥ 3 months.

Phase II:

  1. Patients must be able to provide documented voluntary informed consent.
  2. Male or female patient aged ≥ 18 years.
  3. Histologically or cytologically documented, incurable, locally advanced, recurrent or metastatic cancer, including the following tumor types:

    • Cohort 1: triple negative breast cancer (\< 1% expression for estrogen receptor [ER] and progesterone receptor [PR] and negative)
    • Cohort 2: ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
    • Cohort 3: non-small cell lung cancer
    • Cohort 4: gastric adenocarcinoma or gastroesophageal junction adenocarcinoma (HER2 negative)
    • Cohort 6: HR+/ HER2- breast cancer (≥1% expression for ER and/or PR and HER2 negative)
    • Cohort 7: Head and neck squamous cell carcinoma (including primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx. Other primary tumor sites of HNSCC are not eligible)
    • Cohort 8: Endometrial carcinoma (including carcinosarcoma, but excluding sarcoma and neuroendocrine endometrial carcinoma)
    • Cohort 9: Urothelial carcinoma (including urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, patients with mixed histology are eligible provided urothelial component > 50% and plasmacytoid component\<10%, patients whose tumors contain any neuroendocrine component are not eligible)
    • Cohort 10: Cervical cancer (including squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix) Note: Evaluation of TROP-2 expression is required.
  4. Measurable disease by CT/MRI.
  5. Patients should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies.
  6. ≥ 1.5×109/L, platelet count ≥ 100×109/L, and hemoglobin ≥ 9 g/dL.
  7. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN.
  8. Serum bilirubin ≤ 1.5 ×ULN (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ×ULN may be enrolled), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
  9. Creatinine clearance ≥ 30 mL/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.
  10. ECOG Performance Status 0 or 1.
  11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception during study treatment. Female and male patient treated with SKB264 should continue contraception use for 6 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.

    • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.
    • Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
  12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. Note: Subjects with endocrine AE of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
  13. Expected survival ≥ 3 months.

Exclusion criteria

Exclusion Criteria:

Patients that meet the following criteria will be excluded from entry into the study:

Phase I:

  1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure () III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
  2. Symptomatic or any radiation or surgery for brain metastases within 1 months of first infusion of study drug.
  3. Subjects with second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years).
  4. Require supplemental oxygen for daily activities.
  5. Documented Grade ≥ 2 peripheral neuropathy.
  6. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, corneal disease that prevents/delays corneal healing, macular degeneration.
  7. Subjects previously treated with TROP 2 targeted therapies.
  8. Any standard cancer therapy (e.g. chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.
  9. Any experimental therapy within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.
  10. Any major surgical procedure within 4 weeks of first infusion of study drug.
  11. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.
  12. Have known prior positive test results or medical history for .
  13. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or diabetes ( ≥ 9.0%).
  14. Subjects who require use of strong inhibitors or inducers of at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this study. List of representative examples of strong inhibitors or inducers of CYP3A4 is provided in Appendix III.
  15. Pregnancy or lactation.
  16. \< 45% determined by echocardiogram or multiple gated acquisition scan.
  17. Resting > 480 msec at baseline.
  18. Ascites requiring paracentesis ≥1 per week.
  19. Symptomatic pleural effusion (\< 90% oxygen saturation).
  20. Subjects with non-infectious interstitial lung diseases (ILD) or medical history of pneumonia requiring treatments; severe pulmonary dysfunction caused by lung diseases.
  21. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).
  22. The investigator considers other situations that patients are not appropriate to participate in this trial.

Phase II:

  1. Any patient who was treated in the Phase I part of this study.
  2. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
  3. Subjects with known meningeal , brainstem metastases, spinal cord metastases and/or compression, or other active CNS metastases.
  4. Patients with active second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years, or other malignant cancers that have been cured and no evidence of recurrence).
  5. Require supplemental oxygen for daily activities.
  6. Documented Grade ≥ 2 peripheral neuropathy.
  7. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, corneal disease that prevents/delays corneal healing, macular degeneration.
  8. Patients previously treated with TROP 2 targeted therapies at any time for early stage or metastatic disease.
  9. Any standard cancer therapy (e.g. chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.
  10. Any experimental therapy within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.
  11. Any major surgical procedure within 4 weeks of first infusion of study drug.
  12. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.
  13. Have known prior positive test results or medical history for human immunodeficiency virus.
  14. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or diabetes (HbA1c ≥ 9.0%).
  15. Subjects who require use of strong inhibitors or inducers of CYP3A4 at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this Study. List of representative examples of strong inhibitors or inducers of CYP3A4 is provided in Appendix III.
  16. Pregnancy or lactation.
  17. Left ventricular ejection fraction \< 45% determined by echocardiogram or multiple gated acquisition scan.
  18. Resting QTcF > 480 msec at baseline.
  19. Ascites requiring paracentesis >1 per week.
  20. Symptomatic pleural effusion (\< 90% oxygen saturation).
  21. History of interstitial lung diseases (ILD) or non-infectious pneumonitis requiring steroid treatments; severe pulmonary dysfunction caused by lung diseases.
  22. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).
  23. Known allergic to any components of SKB264, including (including polysorbate-20); or history of severe to another biologic therapy.
  24. The investigator considers other situations that patients are not appropriate to participate in this trial.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,410 participants (actual)

Study arms

  • Experimental
    Phase I: Dose Escalation

    Five dose levels have been selected for evaluation in the Phase I part of the study: 2, 4, 6, 9, and 12 mg/kg of SKB264

    Drug: SKB264

  • Experimental
    Phase II: Triple Negative Breast Cancer

    Histologically documented or cytologically , incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Epithelial Ovarian Cancer

    Histologically documented or cytologically, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Non-Small Cell Lung Cancer

    Histologically documented or cytologically, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

    Histologically or cytologically documented, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Extensive-stage Small Cell Lung Cancer

    Histologically documented or cytologically, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: HR+/ HER2- Breast Cancer

    Histologically documented or cytologically, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Head and Neck Squamous Cell Carcinoma

    Histologically documented or cytologically, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Endometrial carcinoma

    Histologically documented or cytologically, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Urothelial carcinoma

    Histologically or cytologically documented, incurable, locally advanced or metastatic cancer

    Drug: SKB264

  • Experimental
    Phase II: Cervical Cancer

    Histologically or cytologically documented, incurable, locally advanced or metastatic cancer

    Drug: SKB264

Interventions

  • DrugSKB264

    SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

    Also known as: MK-2870, Sacituzumab Tirumotecan (Sac-TMT)

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose (MTD) and Recommended Doses for Expansion (RDEs)

    To determine the maximum tolerated dose (MTD) and/or recommended doses for expansion (RDEs). RDEs will not exceed MTD.

    Time frame: Assess up to 12 months

  2. Phase II: Objective Response Rate (ORR)

    To evaluate the objective response rate (ORR) \[Complete Response (CR) + Partial Response (PR)\] of SKB264 when administered intravenously (IV) as monotherapy at the RDEs to patients with metastatic or locally advanced unresectable tumors.

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

Secondary outcomes

  1. Phase I: Dose Limiting Toxicities (DLTs)

    To determine the dose limiting toxicities (DLTs) of SKB264 when administered IV twice (on Days 1 and 15) every 2 weeks in 4 weeks (28 days) cycles as monotherapy to patients with metastatic or locally advanced unresectable tumors.

    Time frame: Day 28 days after first infusion of study drug

  2. Phase I: Overall safety and tolerability profile

    Percentage of patients with adverse events (AEs), serious adverse events (SAEs), AEs with Grade ≥ 3 per NCI CTCAE v5.0, adverse events of Special Interest (AESI) and AEs related to study drug.

    Time frame: from the date of informed consent until 30 days after last infusion of study drug or begin a new anti cancer therapy, whichever occurs first

  3. Phase I: Preliminary efficacy based on ORR (Objective Response Rate)

    ORR (Objective Response Rate) as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, which will be complete response (CR) + partial response (PR)

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months

  4. Phase I: Preliminary efficacy based on DOR(Duration of Response)

    To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on DOR(Duration of Response).

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months

  5. Phase I: Preliminary efficacy based on PFS(Progression-Free Survival)

    To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on PFS(Progression-Free Survival).

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months

  6. Phase I: Preliminary efficacy based on OS(Overall Survival)

    To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on OS(Overall Survival)

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months

  7. Phase I: Percentage of patients with ADA formation to SKB264.

    To assess the incidence of anti-drug antibody (ADA) formation to SKB264.

    Time frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months

  8. Phase I: PK parameters for SKB264-ADC, SKB264 TAB, and free KL610023 payload.

    To characterize the PK of SKB264-ADC, SKB264 TAB, and free KL610023 payload, such as Cmax

    Time frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months

  9. Phase II: Overall safety and tolerability profile

    Percentage of patients with adverse events (AEs), serious adverse events (SAEs), AEs with Grade ≥ 3 per NCI CTCAE v5.0, adverse events of Special Interest (AESI) and AEs related to study drug.

    Time frame: from the date of informed consent until 30 days after last infusion of study drug or begin a new anti cancer therapy, whichever occurs first

  10. Phase II: Efficacy based on DOR (Duration of Response)

    To evaluate efficacy in patients treated with SKB264 as monotherapy based on DOR(Duration of Response)

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months.

  11. Phase II: Efficacy based on PFS (Progression-Free Survival)

    To evaluate efficacy in patients treated with SKB264 as monotherapy based on PFS (Progression-Free Survival)

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months.

  12. Phase II: Efficacy based on OS (Overall Survival)

    To evaluate efficacy in patients treated with SKB264 as monotherapy based on OS (Overall Survival)

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months.

  13. Phase II: Percentage of patients with ADA formation to SKB264.

    To obtain Percentage of patients with ADA formation to SKB264.

    Time frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months

  14. Phase II: PK parameters for SKB264-ADC, SKB264 TAB, and free KL610023 payload

    To characterize the PK of SKB264-ADC, SKB264 TAB, and free KL610023 payload, such as half life

    Time frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months

  15. Phase II: Levels of TROP2 expression in tumor tissue

    To assess levels of TROP2 expression in tumor tissue and correlation of those levels with responses and toxicity.

    Time frame: Screening and End of Treatment(EOT), approximately 12 months

07

Study locations

109 sites

Showing the first 100 of 109 sites across 6 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Ouyang Q, Rodon J, Liang Y, Wu X, Li Q, Song L, Yan M, Tong Z, Liu Y, Wainberg ZA, Wang Y, Geng C, Ulahannan SV, Yu G, Sharma MR, Wang X, Wang JS, Spira A, Zhao W, Sanborn RE, Cheng Y, Wang X, Liu G, Li Y, Ge J, Chartash E, Akala OO, Yin Y. Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. 2025 Jun 6;18(1):61. doi: 10.1186/s13045-025-01705-2. PubMed 40481574 ↗
  • Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin Y, Xu H, Yu G, Mi Y, Fan Y, Wainberg ZA, Wang X, Su C, Yu Q, Lai S, Sun L, Zhuang W, Wang X, Yang J, Li Y, Ge J, Li J, Zhang L, Fang W. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. Nat Med. 2025 Jun;31(6):1976-1986. doi: 10.1038/s41591-025-03638-2. Epub 2025 Apr 10. PubMed 40210967 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Nov 2025, 69 months.

Of 26 phase 1/2 interventional studies under Carcinoma, Ovarian Epithelial, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 74. This study's 69 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2026 → Nov 2025 and completion Dec 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2019
First posted
Nov 5, 2019
StartActual
Feb 28, 2020
Primary completionActual
Nov 30, 2025was Dec 2026
CompletionEst.
Nov 30, 2027was Dec 2026
Results delay requested
Oct 7, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Nov 30, 2025 (actual)
Oct 9, 2026
Study completion
Dec 31, 2026→Nov 30, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Dec 31, 2026→Nov 30, 2025 (now actual)
    Study completion Dec 31, 2026→Nov 30, 2027
    + 1 other change: registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04152499
Lead sponsor
Klus Pharma Inc.
Responsible party
Sponsor
First posted
Nov 5, 2019
Start date
Feb 28, 2020
Primary completion
Nov 30, 2025
Completion
Nov 30, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Jordi Rodon Ahnert, MD, PhD
study chair · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion